iQflow Starts Clinical Trial of Wearable Insulin Pump for Type 2 Diabetes Patients, First in Korea
[Asia Economy Reporter Eunmo Koo] IoFlow announced on the 8th that it will begin a multicenter clinical trial of a wearable insulin pump targeting insulin-dependent type 2 diabetes patients for the first time in Korea.
IoFlow was selected for the medical device clinical trial support project as part of the "2020 3rd Pan-Government Full-Cycle Medical Device R&D Project," and will conduct a multicenter clinical trial to verify the safety and efficacy of the wearable insulin pump (product name EOPatch) targeting type 2 diabetes patients for the first time in Korea.
This multicenter clinical trial targets 130 type 2 diabetes patients whose blood sugar control is not well managed even with multiple daily insulin injections or multiple mixed insulin therapies. The company aims to provide new diabetes treatment guidelines by comparing the effectiveness of the wearable insulin pump combined with continuous glucose monitoring to that of conventional insulin pumps and multiple daily insulin injection therapies.
With the selection for this medical device clinical trial support project, IoFlow will receive up to 1 billion KRW from the government over three years until 2022, out of approximately 1.1 billion KRW for the clinical trial project targeting type 2 diabetes patients. The multicenter clinical trial will involve Samsung Medical Foundation Gangbuk Samsung Hospital, CHA University Bundang CHA Hospital, Hallym University Pyeongchon Sacred Heart Hospital, and Kangdong Kyung Hee University Hospital.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- [Tomorrow's Weather] Clear Skies Nationwide... Daytime Highs Up to 33°C
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Jaejin Kim, CEO of IoFlow, stated, “The number of type 2 diabetes patients requiring insulin injection for a long duration is about 10 times that of type 1 diabetes patients. Following the successful clinical trial of insulin pumps for type 1 diabetes patients, by entering the type 2 diabetes market, IoFlow will lead a new paradigm in diabetes treatment.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
